News & Events
SAN DIEGO,Oct. 31, 2024/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences.
Details of the company's participation are as follows:
- Truist Healthcare Conference
Details: Viking management will participate in a fireside chat and in 1-on-1 meetings
Conference Date:November 7, 2024
Fireside Chat Timing: 12:30 –1:00 p.m.Eastern onThursday, November 7, 2024
Location:New York, NY - UBS Global Healthcare Conference
Details: Viking management will participate in 1-on-1 meetings
Conference Dates:November 11-14, 2024
Location:Rancho Palos Verdes, CA - Stifel 2024 Healthcare Conference
Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
Conference Dates:November 18-19, 2024
Presentation Timing: 8:35 –9:05 a.m.Eastern onTuesday, November 19, 2024, webcast available
Location:New York, NY - Jefferies London Healthcare Conference 2024
Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
Conference Dates:November 19-21, 2024
Presentation Timing: 9:00 – 9:25 a.m. GMT onThursday, November 21, 2024
Location:London, UK
A live webcast of the Stifel presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section underWebcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visitwww.vikingtherapeutics.com.
SOURCE Viking Therapeutics, Inc.